AstraZeneca PLC

Leading Practices

• AstraZeneca has a clearly defined internal ATM management system, which includes both qualitative and quantitative targets.
• The company discloses several public policy positions on important ATM issues, such as product counterfeiting, pricing, donations, quality management, compulsory licensing, etc.

Changes Compared to Index 2008

• In December 2009, AstraZeneca's began Phase I clinical trials for its first drug candidate for tuberculosis (TB) (AZD5847), out of its Bangalore Research Institute in India.
• To address counterfeiting, AstraZeneca developed a hand-held device to detect counterfeit products, which can be used in Index Countries; in Colombia, the detector is being used as a legal instrument to detect counterfeit products.
• In 2009, AZ began working with Index Countries in sub-Saharan Africa to increase pharmacovigilance awareness and improve systems in that region.

Suggested Areas for Improvement

• AstraZeneca is not transparent in its lobbying and advocacy activities (specifically financial contributions to relevant stakeholder groups) and marketing and promotional programs in Index Countries.
• The company has below average level of activity in tiered pricing and other equitable pricing mechanisms.
• The company has below average level of activity in non-exclusive licensing for its Index Disease products.